The Pharmacotherapeutics of Methylphenidate and Atomoxetine for the Treatment of Childhood Adolescent Attention Deficit- Hyperactivity Disorder

Carol Sibbald, Wesley Sterling, Margaret Bennett, Oonagh McNally, Katherine Rogers*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2122 Downloads (Pure)

Abstract

The most common class of drugs used to treat Attention Deficit-Hyperactivity Disorder (ADHD) are the central nervous stimulants. These drugs stimulate specific areas of the central nervous system and aim to reverse the symptoms of ADHD. Medication for ADHD can be divided into stimulants such as methylphenidate, dexamphetamine, and lisdex amphetaminedimesylate, and non-stimulants such as atomoxetine. This review evaluates and critically discusses the pharmacotherapeutics of and neuronal systems involved in two drugs - methylphenidate and atomoxetine - prescribed for the treatment of ADHD in a paediatric behaviour clinic where children are assessed and treated for ADHD and co-morbid conditions. The presentation and prevalence of ADHD in children is also discussed.
Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalJournal of Healthcare
Volume1
Issue number1
Publication statusPublished - 08 Jun 2017

Bibliographical note

14/03/2021 - this article has been downloaded 2121 times
This demonstrates considerable impact and significant outreach since its publication in July 2017.

Keywords

  • Methylphenidate,
  • Atomoxetine, Pharmacotherapeutics, ADHD

Fingerprint Dive into the research topics of 'The Pharmacotherapeutics of Methylphenidate and Atomoxetine for the Treatment of Childhood Adolescent Attention Deficit- Hyperactivity Disorder'. Together they form a unique fingerprint.

Cite this